Table 7 Economic impact of observed comorbidities (mean total cost) among the populations with one comorbidity. (average cost excluding the related HCV therapy costs)
|
HIV+ Mono-infected patients N = 251 |
HIV/HCV Co-infected patients N = 200 |
Delta between HIV/HCV and HIV+ patients [%] | p-value between HIV/HCV and HIV+ patients | |
|---|---|---|---|---|
| Cardiovascular comorbidities | € 10,116.58 |
€ 20,724.95 € 11,004.28* |
51.19% 8.07%* |
0.001 > 0.050* |
| Neurocognitive impairments | € 7,706.43 |
€ 11,641.29 € 11,641.29* |
33.80% 33.80%* |
< 0.001 < 0.001* |
| HBV infection | € 9,551.84 |
€ 28,790.25 € 13,230.36* |
66.82% 27.80%* |
> 0.050 > 0.050* |
| Bone events | € 8,953.19 |
€ 12,097.29 € 10,972.37* |
25.99% 18.40%* |
> 0.050 > 0.050* |
| Renal impairments | € 9,162.64 |
€ 8038.49 € 8038.49* |
−13.98% − 13.98%* |
> 0.050 > 0.050* |
| Diabetes | € 10,249.13 |
€ 26,723.49 € 11,541.70* |
61.65% 10.99%* |
> 0.050 > 0.050* |
| One-way ANOVA | 0.215 | 0.017 |